Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.68 |
| ▸ | PPARA | Q07869 | 11/20 | 0.68 |
| ▸ | PPARD | Q03181 | 6/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735594 | 0.99 | PPARG (0.67) | PPARGPPARAPPARDS1PR1S1PR5 | |
| SCHEMBL6740462 | 0.99 | PPARG (0.67) | PPARGPPARAPPARDS1PR1S1PR5 | |
| SCHEMBL6735193 | 0.98 | PPARG (0.71) | PPARGPPARAPPARDTDP1 | |
| SCHEMBL6740452 | 0.97 | PPARG (0.64) | PPARGPPARAPPARDS1PR1S1PR5 | |
| SCHEMBL6736579 | 0.97 | PPARG (0.64) | PPARGPPARAPPARDS1PR1S1PR5 | |
| SCHEMBL6738434 | 0.96 | PPARG (0.63) | PPARGPPARAPPARDS1PR1S1PR5 | |
| SCHEMBL6736153 | 0.96 | PPARG (0.63) | PPARGPPARAPPARDS1PR1S1PR5 | |
| SCHEMBL6731876 | 0.96 | PPARG (0.63) | PPARGPPARAPPARDS1PR1S1PR5 | |
| SCHEMBL6739427 | 0.96 | PPARG (0.63) | PPARGPPARAPPARDS1PR1S1PR5 | |
| SCHEMBL6737272 | 0.96 | PPARG (0.65) | PPARGPPARAPPARDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683111-B2 | SUCH AS 2-ETHOXY-3-(4-(2-XANTHEN-9-YLIDENE-ETHOXY)-PHENYL)-PROPIONIC ACID; FOR TREATING CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TREATMENT OF DIABETES/OBESITY | NOVO NORDISK A/S (DK) | 2004-01-27 | — | — | US | claimed |
| US-20020115654-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | claimed |
| EP-1123267-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2001-08-16 | — | — | EP | claimed |
| WO-2000023415-A1 | NEW COMPOUNDS, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-04-27 | — | — | WO | claimed |
| US-6683111-B2 | SUCH AS 2-ETHOXY-3-(4-(2-XANTHEN-9-YLIDENE-ETHOXY)-PHENYL)-PROPIONIC ACID; FOR TREATING CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; TREATMENT OF DIABETES/OBESITY | NOVO NORDISK A/S (DK) | 2004-01-27 | — | — | US | disclosed |
| US-20020115654-A1 | New compounds, their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| US-6353018-B1 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2002-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115654-A1 | New compounds, their preparation and use | PPARG, PPARD, PPARA | PPARG 1/4885PPARA 3/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.